CDIOCardio Diagnostics Holdings Inc
$1.73
$0.0103
(0.60%)
EarningsAug 13
Mkt Cap$5.09M
Vol4,097.00
Cardio Diagnostics Holdings (NASDAQ: CDIO) Showcases Precision Cardiovascular Solutions for Employers, Health Plans
Cardio Diagnostics Holdings (NASDAQ: CDIO) is a precision cardiovascular medicine company leveraging epigenetics, genetics and artificial intelligence. The company discussed innovative approaches to cardiovascular disease prevention, risk assessment and cost management at multiple national benefits conferences this month. Cardio’s presentations highlight how advanced cardiovascular risk assessment and detection tools can support both improved health outcomes and more […]
Investor Brand Network
Cardio Diagnostics Holdings (NASDAQ: CDIO) Leverages Epigenetics to Reveal Hidden Heart Disease Risks
When most people think about their risk for heart disease, they think about family history. Did a parent or grandparent have a heart attack? Is heart disease “in their genes”? It’s an understandable assumption, and genetics does play a role in cardiovascular risk. But a growing body of research suggests that DNA sequence alone tells […]
Investor Brand Network
Cardio Diagnostics Holdings (NASDAQ: CDIO) Brings Molecular Precision to a Blind Spot in Coronary Heart Disease Detection
Coronary heart disease (“CHD”) remains the leading cause of death in the United States, but the tools doctors have long relied on to detect it early are proving less reliable than many patients assume. Cardio Diagnostics Holdings (NASDAQ: CDIO) reports that approximately 50% of individuals with coronary heart disease do not present with traditional risk factors and conventional […]
Investor Brand Network
Cardio Diagnostics Holdings (NASDAQ: CDIO) Expands Coverage of Precision Cardiovascular Tests Through Atlas Healthcare Physicians
Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD(TM) and PrecisionCHD(TM) tests for eligible members with prior authorization. The coverage expands access to physician-ordered blood tests […]
Investor Brand Network
Atlas Healthcare Physicians to Cover Cardio Diagnostics Precision Cardiovascular Medicine Tests Across Its Network
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians (AHP), a community-driven, independent physician association (IPA) based in Southern California, will cover Cardio Diagnostics tests, Epi+Gen CHD and...
Business Wire
Cardio Diagnostics Holdings (NASDAQ: CDIO) Targets a $393B Heart Disease Problem with Epigenetics and AI
Heart disease has held the grim distinction of being the leading cause of death in the United States for decades, and despite advances in medicine, the problem is getting worse, not better. According to the American Heart Association (“AHA”), cardiovascular disease accounted for more than 940,000 deaths in the United States in 2022, maintaining its position as the […]
Investor Brand Network
Cardio Diagnostics Holdings (NASDAQ: CDIO) Aligns with Growing Shift Toward Predictive, Precision Medicine
Cardio Diagnostics Holdings (NASDAQ: CDIO) is focused on personalized, data-driven cardiovascular care powered by artificial intelligence, epigenetics and genetic insights. “Through its proprietary platform and expanding testing capabilities, the company is pursuing a future in which prevention becomes more accessible, scalable and actionable before life-threatening cardiac events occur,” reads a recent article. “The company’s vision reflects a […]
Investor Brand Network
Cardio Diagnostics Holdings (NASDAQ: CDIO) Working to Help Employers Tackle Cardiovascular Risk, Healthcare Costs
A single heart attack or major cardiovascular event can have consequences that extend far beyond a patient’s health, affecting employers, insurers and healthcare systems through higher medical costs, lost productivity and long-term care expenses. As cardiovascular disease continues to drive a significant share of healthcare spending, organizations responsible for employee benefits are seeking new strategies […]
Investor Brand Network
Cardio Diagnostics (NASDAQ: CDIO) Harnesses AI, Genetics and Epigenetics to Advance Cardiovascular Risk Detection
Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discusses the urgent need for more effective tools to identify risk earlier and guide personalized intervention strategies for cardiovascular disease. The piece reads, “Cardio Diagnostics is rising to the challenge by developing a suite of clinical, population health and biopharma solutions designed to leverage artificial […]
Investor Brand Network
Cardio Diagnostics Holdings (NASDAQ: CDIO) Showcases AI-Powered Cardiovascular Risk Solutions at Four National Benefits Conferences
Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD(TM), PrecisionCHD(TM) […]
Investor Brand Network
<
1
2
...
>
Advertisement|Remove ads.
Latest CDIO News
ViewCardio Diagnostics Holdings (NASDAQ: CDIO) Showcases Precision Cardiovascular Solutions for Employers, Health Plans
Investor Brand Network
Cardio Diagnostics Holdings (NASDAQ: CDIO) Leverages Epigenetics to Reveal Hidden Heart Disease Risks
Investor Brand Network
Cardio Diagnostics Holdings (NASDAQ: CDIO) Brings Molecular Precision to a Blind Spot in Coronary Heart Disease Detection
Investor Brand Network
Advertisement|Remove ads.